Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 79,3 M
EBIT 2017 7,39 M
Net income 2017 -2,93 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 119 M
EBIT 2018 18,5 M
Net income 2018 7,12 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 55,44
EV / Sales2017 5,17x
EV / Sales2018 3,43x
Capitalization 337 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
08/08 TELIGENT : reports 2Q loss
08/08 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Results of Operations and Financial ..
08/08 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
08/08 Teligent, Inc. Announces Second Quarter 2017 Results
08/08 TELIGENT INC : Investor Network: Teligent, Inc. to Host Earnings Call
07/28 Teligent, Inc. to Hold Conference Call for Second Quarter 2017 Results
07/27 TELIGENT : Announces FDA Approval Of Erythromycin Topical Gel USP, 2%
07/21 TELIGENT, INC. : Announces FDA Approval Of Erythromycin Topical Gel USP, 2%
05/26 TELIGENT : Commerce Bank Has $145,000 Stake in Teligent Inc
05/24 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Submission of Matters to a Vote of S..
More news
Sector news : Pharmaceuticals - NEC
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/17 Exclusive - Taking aim at China, India tightens power grid, telecoms rules
08/16 Seven charged in U.S. insider trading ring
08/16DJBayer Joins Fight Against Citrus Greening Disease
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,40 $
Spread / Average Target 49%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI337
JOHNSON & JOHNSON15.77%360 112
NOVARTIS10.12%220 515
ROCHE HOLDING LTD.5.33%218 264
PFIZER2.71%198 663
MERCK AND COMPANY6.51%171 005